Breaking News Headlines Today

News from neurologylive.com

See all of neurologylive.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve discovered 358 headlines written by neurologylive.com during the past 3 months.

Ground News rates neurologylive.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

neurologylive.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about neurologylive.com

Where is neurologylive.com located?neurologylive.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Novartis Phase III Trials Show Ianalumab Significantly Improves Outcomes in Sjögren’s Disease

Open the article to view the coverage from EuropaWire.eu See the Story

Overviewing 36-Month, Phase 1b Data Testing Gene Therapy AB-1005 in Parkinson Disease: Nisha Chhabria MD, FAAN

The medical director of CNS Clinical Development at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]Read Article

Building a Clinical Trial Framework to Study GLP-1 RAs in Stroke-Related Conditions: Dennis Rivet, MD

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed the next steps in advancing GLP-1s for idiopathic intracranial hypertension and the research necessary to further understand their therapeutic impact. [WATCH TIME: 3 minutes]Maryland · Maryland Read Article

Target Trial Emulation Favors Rituximab’s Effectiveness Over Cladribine in Treating Multiple Sclerosis

A new study reveals rituximab outperforms cladribine in managing MRI disease activity in relapsing multiple sclerosis over 4.5 years.Read Article

Measuring Sleep Duration and Identifying Phenotypes Linked to Cognitive Decline in Hispanic Populations

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.Maryland · Maryland Read Article

Phase 2 GABriella Study Represents First Step in Testing Selective Novel Y-Secretase Modulators for Prodromal Alzheimer Disease

Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.Alzheimer's Disease Read Article

Standard of Care and Dravet Syndrome–Specific ASMs: Mechanisms and Risk Management

Panelists discuss how the treatment paradigm for Dravet syndrome has dramatically shifted with newer FDA-approved medications (cannabidiol, stiripentol, and fenfluramine) now recommended as first- and second-line therapies alongside traditional options such as valproate and clobazam, emphasizing that these novel mechanisms offer distinct advantages and should be used early rather than as last-resort treatments, with risk evaluation and mitigatio…Read Article

Risk Factors and Risk Mitigation Strategies of SUPED for Patients With Dravet Syndrome

Panelists discuss how patients with Dravet syndrome face elevated sudden unexplained death in epilepsy (SUDEP) risk compared with other epilepsy populations, emphasizing the importance of early family education about risk factors such as convulsive seizures and medication adherence, while highlighting that newer therapies show promise in reducing both seizure frequency and SUDEP risk through better seizure control and decreased status epilepticu…Read Article

Higher Levels of Postpartum Depression in Women With MS Raise Importance for Screening Efforts

A new study reveals higher rates of postpartum depression in women with multiple sclerosis, emphasizing the need for early screening and management strategies.Read Article

News from neurologylive.com

News from neurologylive.com

Information about neurologylive.com

Media Bias Ratings

Factuality

Ownership

Top neurologylive.com News

Fda Approves Ajovy for Migraine Prevention in Children and Teens

B Cells as a Treatment Target In Myasthenia Gravis

Novartis Phase III Trials Show Ianalumab Significantly Improves Outcomes in Sjögren’s Disease

Overviewing 36-Month, Phase 1b Data Testing Gene Therapy AB-1005 in Parkinson Disease: Nisha Chhabria MD, FAAN

Building a Clinical Trial Framework to Study GLP-1 RAs in Stroke-Related Conditions: Dennis Rivet, MD

Target Trial Emulation Favors Rituximab’s Effectiveness Over Cladribine in Treating Multiple Sclerosis

Measuring Sleep Duration and Identifying Phenotypes Linked to Cognitive Decline in Hispanic Populations

Phase 2 GABriella Study Represents First Step in Testing Selective Novel Y-Secretase Modulators for Prodromal Alzheimer Disease

Standard of Care and Dravet Syndrome–Specific ASMs: Mechanisms and Risk Management

Risk Factors and Risk Mitigation Strategies of SUPED for Patients With Dravet Syndrome

Higher Levels of Postpartum Depression in Women With MS Raise Importance for Screening Efforts

Similar News Topics

Topics Most Covered by neurologylive.com

Sources Covering Similar Topics

Breaking News Topics Related to neurologylive.com

Information about neurologylive.com

Media Bias Ratings

Factuality

Ownership

Overviewing 36-Month, Phase 1b Data Testing Gene Therapy AB-1005 in Parkinson Disease: Nisha Chhabria MD, FAAN

Building a Clinical Trial Framework to Study GLP-1 RAs in Stroke-Related Conditions: Dennis Rivet, MD

Target Trial Emulation Favors Rituximab’s Effectiveness Over Cladribine in Treating Multiple Sclerosis

Measuring Sleep Duration and Identifying Phenotypes Linked to Cognitive Decline in Hispanic Populations

Phase 2 GABriella Study Represents First Step in Testing Selective Novel Y-Secretase Modulators for Prodromal Alzheimer Disease

Standard of Care and Dravet Syndrome–Specific ASMs: Mechanisms and Risk Management

Risk Factors and Risk Mitigation Strategies of SUPED for Patients With Dravet Syndrome

Higher Levels of Postpartum Depression in Women With MS Raise Importance for Screening Efforts